Advances, challenges, and limitations in serum-proteome-based cancer diagnosis

Otto-von-Guericke-Universität Magdeburg, Magdeburg, Saxony-Anhalt, Germany
Journal of Proteome Research (Impact Factor: 5). 02/2006; 5(1):19-25. DOI: 10.1021/pr050271e
Source: PubMed

ABSTRACT Recent advances in medicine have dramatically reduced the incidence and mortality of many cardiovascular, infectious, and certain neoplastic diseases; the overall mortality for most malignant solid tumors remains high. The poor prognosis in these cancers is due, in part, to the absence of adequate early screening tests, leading to delays in diagnosis. Three strategies have been applied to fight cancer: analysis of the molecular mechanisms involved in its pathogenesis and progression, improvement of early diagnosis, and the development of novel treatment strategies. There have been major advances in our understanding of cancer biology and pathogenesis and in the development of new (targeted) treatment modalities. However, insufficient progress has been made with respect to improving the methods for the early diagnosis and screening of many cancers. Therefore, cancer is often diagnosed at advanced stages, delaying timely treatment and leading to poor prognosis. Proteome analysis has recently been used for the identification of biomarkers or biomarker patterns that may allow for the early diagnosis of cancer. This tool is of special interest, since it allows for the identification of tumor-derived secretory products in serum or other body fluids. In addition, it may be used to detect reduced levels or loss of proteins in the serum of cancer patients that are present in noncancer individuals. These changes in the serum proteome may result from cancer-specific metabolic or immunological alterations, which are, at least partly, independent of tumor size or mass, thereby facilitating early discovery.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Conventional protein detection methods such as enzymelinked immunosorbent assays (ELISA) often take many hours to complete and usually only apply to one protein at a time. More rapid, multiplexed methods are needed for point-of-care (POC) and surgical applications in future personalized cancer diagnostics and therapy. This paper describes a low-cost inkjetprinted gold nanoparticle (AuNP) sensor chip integrated into a simple microfluidic immunoarray to achieve detection of two cancer biomarker proteins in 5 mL samples in 8 min. Magnetic beads of 1 mm diameter derivatized with ~300 000 enzyme labels and thousands of antibodies were used to capture the biomarker proteins from samples. The beads with captured proteins are then injected into the microfluidic system and captured by antibodies on nanostructured sensor elements to provide high sensitivity and ultralow detection limits (DL). For assay times of 45 mins, DLs were 78 fgmL�1 for interleukin-6 (IL-6) and 19 fg mL�1 for interleukin-8 (IL-8). Decreasing assay time to 8 min provided clinically relevant DLs of 5 pgmL�1. Accuracy was demonstrated by determining IL-6 and IL-8 in conditioned media from head and neck squamous cell carcinoma (HNSCC) cells and comparing results to those from standard single-protein ELISAs. Results suggest that this device can be employed for rapid detection of a wide range of disease-related proteins in clinical applications
    ChemistryOpen 08/2013; 2(4):141-145. DOI:10.1002/open.201300018 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The demand for high sensitivity in microarray technology has stimulated the research of new labeling strategies, new substrates with increased loading capacity and new approaches to amplify the fluorescence signals. Although these methods improve the sensitivity, they are based on non-routine procedures which limit their widespread usage. A simple way to achieve fluorescence enhancement is the optical interference (OI) coating technology based on the use of substrates with films of well-defined thickness that maximize photoabsorption of the dye molecules in the vicinity of the surface and reflect the emitted light toward the detector. Here we introduce a new substrate for fluorescence enhancement composed of a thin aluminum mirror and a single quarter wave silicon oxide as a dielectric layer. The use of such material allows the development of a substrate suited for parallel production in conventional IC (Integrated Circuit's) technology, which produces a 20-fold enhancement of fluorescence compared to glass, which is the most common material used in microarrays. The new substrate was coated with a copolymer of N,N-dimethylacrylamide, N-acryloyloxysuccinimide, and 3-(trimethoxysilyl)propyl methacrylate, copoly(DMA-NAS-MAPS), which forms, by a simple and robust procedure, a functional nanometric film that covalently binds bio-probes on the surface and efficiently suppresses non-specific adsorption. The performance of the new fluorescence-enhancing substrate in microarray technology was demonstrated for the detection of a panel of inflammation biomarkers pushing detection limits into the femtomolar range.
    Sensors and Actuators B Chemical 03/2014; 192:15–22. DOI:10.1016/j.snb.2013.09.119 · 3.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer can be easily treated when found early. A probe capable of detecting cell transformation may increase the success rate of early diagnosis of cancer. In this report we have tested the ability of a fluorescent, quadruplex DNA binding probe, 3,6-bis(1-methyl-4- vinylpyridinium) carbazole diiodide (BMVC), to detect cell transformation in vitro. BMVC was applied to living cells in several different models of cell transformation, and the fluorescence signals of BMVC were measured. The degrees of cell transformation in these models were characterized by alterations in cellular morphological phenotype and subcellular organization. When BMVC probes were applied, the number of BMVC-positive cells increased in accordance with the degree of transformation. BMVC was capable of significantly detecting formation of foci, increased cellular motility, cell proliferation, cell apoptosis, anchorage-independent growth, and increased invasiveness of transformed cells. These results demonstrate the ability of BMVC probes to detect cell transformation and indicate that BMVC is of promise for use as a probe in early cancer detection.
    PLoS ONE 01/2014; 9(1):e86143. DOI:10.1371/journal.pone.0086143 · 3.53 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014